Clinical Trials Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.

Total 421 results

Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

"SALT-2 Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Hyponatremia | Inappropriate ADH Syndrome | Water Intoxication | Water-electrolyte Imbalance

Germany
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients (INSIGHT)

Hyponatremia

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...
Quintiles, Inc.

Completed

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia (EQUATOR)

Acute Schizophrenia

United States, Malaysia, Serbia, Ukraine, Romania, Puerto Rico, Colombia, Turkey
Otsuka Pharmaceutical Development & Commercialization...
i3 Innovus

Completed

Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)

Depressive Disorder, Major
Akebia Therapeutics
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Anemia

United States, Italy, Spain, Hungary, Czechia, Poland
Otsuka Pharmaceutical Development & Commercialization...
Syneos Health

Terminated

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

Belgium, Spain, United States, United Kingdom, Italy, Germany, Czechia, Romania
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Canada Pharmaceutical Inc.; Lundbeck Canada Inc.

Completed

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Major Depressive Disorder

Canada
Syneos Health
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

Healthy Volunteers

Australia
Otsuka Pharmaceutical Development & Commercialization...
Syneos Health

Terminated

Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

United States, United Kingdom, Italy
Otsuka Pharmaceutical Development & Commercialization...
Click Therapeutics, Inc.

Completed

Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder (MIRAI)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
IQVIA Pvt. Ltd

Terminated

Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

Crohn's Disease

United States, Poland
Otsuka Pharmaceutical Development & Commercialization...
PRA Health Sciences

Completed

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

Schizophrenia | Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Iqvia Pty Ltd

Terminated

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

Post-traumatic Stress Disorder (PTSD)

United States
Inha University Hospital
Otsuka Pharmaceutical Development & Commercialization, Inc.

Unknown

Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease (Challenge)

Cerebral Small Vessel Disease

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...
PRA Health Sciences

Completed

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Schizophrenia | Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Tolvaptan in Hyponatremic Cancer Patients

Advanced Cancers

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder

Bipolar I Disorder | Manic Episode

United States, Croatia, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder | Manic Episode

Serbia, United States, Bulgaria, Poland
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

Nervous System Diseases | Mental Disorder | Alzheimer's Type | Agitation Associated With Alzheimer's Disease

United States, Germany, France, Bulgaria, Spain, Slovenia, Croatia, Serbia, Russian Federation, Ukraine, Canada, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Active, not recruiting

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Irritability Associated With Autism Spectrum Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer's Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer Dementia | Agitation Associated With Alzheimer's Dementia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Withdrawn

Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

Major Depressive Disorder (MDD)
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

Spain, United States, Germany, Croatia, Serbia, Russian Federation, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.

Bipolar I Disorder | Acute Mania

United States, Serbia, Bulgaria, Croatia, Poland, Ukraine
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Myeloma

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (Anchor)

Irritability Associated With Autism Spectrum Disorder (ASD)

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Stress Disorders, Post-Traumatic

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

France, United States, Bulgaria, Slovenia, United Kingdom, Russian Federation, Ukraine, Finland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder (ATLAS)

Bipolar I

United States, France, Romania, Poland, Canada, Hungary, Japan, Korea, Republic of, Malaysia, Taiwan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

Bipolar I Disorder

United States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Germany, Poland, Hungary, Slovakia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

ADHD | Conduct Disorder | Oppositional Defiant Disorder | Autism | Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Terminated

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Nervous System Diseases | Schizophrenia | Mental Disorder

United States
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

STAT3 Inhibitor for Solid Tumors

Solid Tumor | Advanced Cancer

United States
Dallas VA Medical Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Unknown

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

Helicobacter Infection

United States
Durham VA Medical Center
Otsuka Pharmaceutical Development and Commercialization, Inc.

Unknown

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole (DIMES)

Schizophrenia | Major Depressive Disorder | Schizo Affective Disorder | Bi-Polar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Active, not recruiting

Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Pulmonary TB

South Africa
Guido Tricot
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

Busulfan in Multiple Myeloma

Multiple Myeloma
Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Completed

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

Pulmonary TB

South Africa
University of Michigan Rogel Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Of Double Umbilical Cord Blood Transplantation

Hematological Malignancies

United States

Clinical Trials Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations